Brown Advisory Inc Crispr Therapeutics Ag Transaction History

Brown Advisory Inc

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$51.17 - $68.18 $25,585 - $34,090	500 Added 13.39%	4,234 $228,000
Q1 2024 Apr 24, 2024	SELL	$60.67 - $89.12 $1,274 - $1,871	-21 Reduced 0.56%	3,734 $254,000
Q4 2023 Feb 08, 2024	BUY	$38.62 - $72.18 $145,018 - $271,035	3,755 New	3,755 $235,000
Q3 2022 Nov 14, 2022	BUY	$61.1 - $83.78 $57,922 - $79,423	948 Added 23.07%	5,057 $331,000
Q2 2022 Nov 14, 2022	SELL	$43.23 - $73.83 $9,510 - $16,242	-220 Reduced 5.08%	4,109 $249,000
Q1 2022 Nov 14, 2022	BUY	$53.19 - $79.24 $230,259 - $343,029	4,329 New	4,329 $272,000
Q1 2022 May 09, 2022	SELL	$53.19 - $79.24 $162,069 - $241,444	-3,047 Closed	0 $0
Q4 2021 Jan 27, 2022	SELL	$70.09 - $111.29 $2,102 - $3,338	-30 Reduced 0.97%	3,047 $231,000
Q3 2021 Nov 12, 2021	SELL	$110.2 - $156.64 $114,828 - $163,218	-1,042 Reduced 25.3%	3,077 $344,000
Q2 2021 Jul 29, 2021	BUY	$100.84 - $161.89 $4,033 - $6,475	40 Added 0.98%	4,119 $667,000
Q1 2021 May 14, 2021	BUY	$110.72 - $210.04 $117,031 - $222,012	1,057 Added 34.98%	4,079 $497,000
Q4 2020 Feb 12, 2021	BUY	$79.67 - $173.23 $240,762 - $523,501	3,022 New	3,022 $462,000

485

57.5M

1.09M

1.9M

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $3.12B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

Get notified when there are updates to the investment portfolio of Brown Advisory Inc, based on Form 13F filings with the SEC.

Stay updated on Brown Advisory Inc with notifications on news.